Testosterone Enanthate and Cannabis: Full Interaction Profile

What Does Cannabis Actually Do to Testosterone Levels?

Acute and chronic cannabis exposure measurably reduces circulating testosterone in men through hypothalamic-pituitary-gonadal (HPG) axis suppression. A 2019 analysis published in the World Journal of Men's Health found that men reporting current cannabis use had significantly lower serum testosterone compared with never-users, with the association strongest in daily users [1]. Because testosterone enanthate therapy is already suppressing endogenous production via negative feedback, adding cannabis introduces a second suppressive signal on top of an axis that is pharmacologically muted.

THC and the HPG Axis

THC binds cannabinoid receptor type 1 (CB1R), which is expressed on hypothalamic GnRH neurons and pituitary gonadotrophs [2]. Activation of CB1R reduces GnRH pulse amplitude, which in turn lowers LH and FSH secretion. A controlled crossover study (N=27) showed that acute THC administration reduced serum LH by roughly 30% within two hours compared with placebo [3].

On exogenous TE, endogenous LH is already suppressed to near-zero. The clinical consequence is not a further drop in circulating testosterone (the injected ester covers that), but rather accelerated testicular atrophy and impaired spermatogenesis for patients who retain fertility goals. Men on TE who also use cannabis daily may face more complete gonadal suppression than those using TE alone.

Chronic Use and Serum Androgen Trajectory

Chronic daily cannabis use is associated with lower testosterone trajectories over time. The National Health and Nutrition Examination Survey (NHANES) 2011 to 2016 cross-sectional data (N=1,577 men) showed an inverse dose-response relationship between cannabis use frequency and total testosterone, with the heaviest users showing mean testosterone approximately 64 ng/dL below non-users after covariate adjustment [4]. That gap is clinically meaningful when a prescriber is trying to optimize a patient to a target range of 500 to 900 ng/dL on TE therapy.

CYP Enzyme Competition: The Pharmacokinetic Layer

Testosterone enanthate is hydrolyzed to free testosterone after injection, and free testosterone undergoes hepatic metabolism primarily via CYP3A4, with secondary contributions from CYP2C9 and CYP2C19 [5]. CBD, the second major cannabinoid in most commercial cannabis products, is a well-characterized inhibitor of CYP3A4 and CYP2C9 [6].

CBD's Inhibitory Effect on CYP3A4

The FDA's 2018 pharmacology review for Epidiolex (cannabidiol oral solution) documented that CBD inhibits CYP3A4 at clinically achievable plasma concentrations, raising the area under the curve (AUC) of co-administered CYP3A4 substrates [7]. Testosterone is a recognized CYP3A4 substrate. When CYP3A4 is inhibited, testosterone clearance slows, which could transiently raise free testosterone above the intended therapeutic window.

Supraphysiologic free testosterone carries its own risks: increased erythrocytosis (hematocrit rising above 54%), worsening of sleep apnea, and accelerated prostate growth in susceptible individuals [8]. A patient using a CBD-rich product alongside TE injections without disclosing this to their provider could inadvertently push their levels into a range associated with adverse events.

THC and Drug Metabolism

THC itself is metabolized by CYP2C9 and CYP3A4. It may act as a competitive substrate rather than a pure inhibitor, meaning the two compounds (THC and testosterone) compete for the same enzymatic machinery [9]. The net pharmacokinetic effect depends on the THC:CBD ratio in the product used and the patient's baseline CYP3A4 activity, which varies significantly by genetics (CYP3A4*22 carriers have 50% reduced baseline activity).

HealthRX CYP Interaction Risk Tier for TE Plus Cannabis:

| Cannabis Product Type | Dominant Cannabinoid | CYP Risk Level | Monitoring Adjustment | |---|---|---|---| | High-THC flower or concentrate | THC | Moderate (competitive substrate) | Check trough testosterone at 6 weeks | | Full-spectrum CBD oil (greater than 10 mg/day CBD) | CBD | High (CYP3A4 inhibitor) | Check trough testosterone at 4 weeks plus hematocrit | | CBD isolate (less than 5 mg/day) | CBD | Low to moderate | Standard monitoring schedule | | Balanced 1:1 THC:CBD product | Both | High (additive CYP effects) | Check trough testosterone at 4 weeks plus full metabolic panel |

Cardiovascular Risk: Two Agents, One Heart

Testosterone enanthate at supraphysiologic doses raises hematocrit, increases platelet aggregation, and may promote left ventricular hypertrophy [10]. Cannabis, particularly high-THC cannabis, acutely raises heart rate by 20 to 50 beats per minute and transiently elevates blood pressure in naive users, with chronic heavy use associated with cardiomyopathy [11].

Shared Hemodynamic Burden

The American Heart Association's 2020 scientific statement on cannabis and cardiovascular disease concluded that cannabis use is associated with increased risk of acute myocardial infarction, atrial fibrillation, and stroke, with the risk elevated in individuals with pre-existing cardiovascular risk factors [12]. Men receiving TRT often carry baseline cardiovascular risk: older age, metabolic syndrome, or prior cardiovascular events.

The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, found that testosterone therapy in hypogonadal men with high cardiovascular risk did not increase major adverse cardiovascular events compared with placebo over a mean follow-up of 33 months [13]. That result applied to men on controlled testosterone therapy without documented concurrent cannabis use. Extrapolating TRAVERSE safety data to daily cannabis users on TE is not supported by the trial design.

Polycythemia and Thrombotic Risk

TE raises hematocrit. Cannabis smoking adds carboxyhemoglobin, reducing oxygen-carrying efficiency and creating additional stimulus for erythropoietin release. Combined, these effects may push hematocrit higher than TE alone would predict. The Endocrine Society's 2018 Clinical Practice Guideline on testosterone therapy recommends discontinuing therapy if hematocrit exceeds 54% [8]. Patients using both agents should have hematocrit checked every 3 months rather than the standard 6-month interval.

Effect on Libido and Sexual Function: Mixed Signals

One reason patients use cannabis alongside TRT is perceived enhancement of libido or sexual experience. The pharmacological reality is more complicated.

Short-Term Reports vs. Long-Term Data

Survey data suggest that acute cannabis use may enhance subjective sexual pleasure in some individuals [14]. At the same time, chronic daily THC exposure is associated with reduced sexual desire and erectile dysfunction via CB1R-mediated suppression of nitric oxide synthesis in penile vascular tissue [15]. A man on TE who uses cannabis daily may find that the testosterone-driven libido improvement is partially offset by cannabinoid-mediated vascular and neurochemical effects.

Dopamine Pathway Overlap

Both exogenous testosterone and THC modulate mesolimbic dopamine signaling. Testosterone increases dopamine receptor sensitivity in reward pathways [16], while THC produces acute dopamine release followed by blunted dopaminergic response with chronic use [17]. The net effect on motivation and sexual drive in men using both agents simultaneously has not been studied in a dedicated trial, so no clean prediction is possible.

Cannabis, Testosterone, and Body Composition

Myotrophic Goals and Appetite Dysregulation

Many patients begin TE therapy partly for lean mass gain. Cannabis, particularly THC, stimulates appetite via hypothalamic CB1R activation and ghrelin release [18]. Caloric surplus from cannabis-induced appetite stimulation may undermine body composition goals, increasing fat mass even as TE promotes lean mass accretion. The two agents work against each other metabolically if body recomposition is the therapeutic target.

Insulin Sensitivity Considerations

A cross-sectional study in Diabetes Care (N=4,657) found that current cannabis users had lower fasting insulin and smaller waist circumference than non-users, suggesting a potential metabolic benefit [19]. Testosterone therapy also improves insulin sensitivity in hypogonadal men with type 2 diabetes [20]. Whether cannabis and TE have additive or merely overlapping insulin-sensitizing effects is unknown, and patients with diabetes should monitor glucose more closely when introducing either agent.

Mental Health and Cognitive Overlap

Anxiety and Mood Effects

TE at therapeutic doses generally improves mood, reduces irritability, and decreases depressive symptoms in hypogonadal men [21]. High-THC cannabis may increase anxiety, paranoia, and in predisposed individuals, psychotic symptoms, particularly at doses above 10 mg THC [22]. A patient reporting worsening mood instability on TRT should be asked about concurrent cannabis use before attributing the symptom change to testosterone dose.

Sleep Architecture

Both TE and THC affect sleep. TE can worsen sleep apnea through upper airway changes. THC acutely reduces REM sleep, which may mask apnea-related arousals short term but degrades sleep quality over chronic use [23]. Patients using both agents who report non-restorative sleep or excessive daytime fatigue need polysomnography consideration, not simply a testosterone dose adjustment.

What to Tell Your Prescriber: Disclosure Protocol

The FDA label for testosterone enanthate (NDA 009165) does not list cannabis as a named drug interaction, but it does require disclosure of all medications and substances, as cannabinoids are not pharmacologically inert with respect to CYP enzymes and the HPG axis [24].

Why Disclosure Changes Clinical Management

Disclosing cannabis use changes three management decisions:

1. Monitoring frequency: hematocrit and testosterone trough checks shift from every 6 months to every 3 to 4 months.
2. Dose titration: if CBD is inhibiting CYP3A4, the prescriber may need to target a lower TE dose to avoid supraphysiologic peaks.
3. Cardiovascular screening: baseline ECG and blood pressure monitoring become more important when both agents are in use.

The Endocrine Society guideline states: "Clinicians should inform patients of the potential risks and benefits of testosterone therapy and monitor patients on testosterone therapy with regular assessment of symptom response and laboratory values." [8] That monitoring framework assumes accurate substance disclosure.

Timing and Route of Cannabis Use

Smoked cannabis delivers peak THC within minutes, with acute HPG suppression lasting 2 to 4 hours. Oral cannabis (edibles) produces a delayed peak at 1 to 3 hours with effects lasting up to 8 hours, meaning oral forms may produce more sustained CYP enzyme competition throughout the day. Patients who use edibles daily give CBD more continuous access to CYP3A4 than occasional smokers, which is relevant to how frequently testosterone levels should be checked.

Alcohol and Testosterone Enanthate: A Brief Note

Secondary queries around alcohol and TE warrant a direct answer. Acute alcohol intake suppresses testosterone synthesis by impairing Leydig cell function and increasing cortisol [25]. On TE therapy, endogenous production is already suppressed, so the acute alcohol-testosterone effect is less pronounced than in men with intact HPG axes. The more relevant concern is that chronic heavy alcohol use (more than 14 standard drinks per week) impairs hepatic metabolism and may alter testosterone ester clearance [26]. Light to moderate alcohol use (up to 7 drinks per week) does not appear to meaningfully alter TE pharmacokinetics based on available pharmacokinetic modeling, but concurrent heavy drinking should be disclosed for the same CYP-metabolism reasons that apply to cannabis.

Monitoring Schedule for Patients Using Both Agents

Patients on testosterone enanthate who use cannabis should follow an intensified monitoring schedule compared with the standard Endocrine Society protocol.

Recommended Laboratory Intervals

• Total and free testosterone (trough, drawn just before next injection): weeks 6, 12, and 24 in the first year, then every 3 to 4 months ongoing.
• Hematocrit and hemoglobin: every 3 months for the first year.
• Comprehensive metabolic panel: every 6 months.
• Lipid panel: every 6 months (both TE and chronic cannabis may shift HDL downward).
• PSA (men over 40): every 6 months.
• Blood pressure: at every clinical contact.

If hematocrit exceeds 54%, TE should be held and the cannabis use pattern reassessed, as smoking cannabis adds independent polycythemia risk through carboxyhemoglobin-driven EPO stimulation.